agenusbio.com

Webbplats analys agenusbio.com

Agenus: Better immunotherapies

 Genereras på Mars 28 2026 02:34 AM

Gammal statistik? UPDATERA !

Ställningen är 54/100

SEO Innehåll

Titel

Agenus: Better immunotherapies

Längd : 30

Perfekt, din titel innehåller mellan 10 och 70 tecken.

Beskrivning

Activating the Power of the Immune System to Defeat Cancer

Längd : 58

Idealisk, din metabeskrivning bör innehålla mellan 70 och 160 tecken (mellanslag räknas som tecken). Använd denna gratis verktyg för att räkna ut textlängden.

Nyckelord

Mycket dåligt. Vi har inte lyckats hitta några meta-taggar på din sida. Använd denna meta-tag generator, gratis för att skapa nyckelord.

Og Meta Egenskaper

Bra, din sida drar nytta utav Og.

Egendom Innehåll
type website

Rubriker

H1 H2 H3 H4 H5 H6
2 24 65 0 0 0
  • [H1] Using Your Immune System to Defeat Cancer
  • [H1] Using Your Immune System to Defeat Cancer
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
  • [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
  • [H2] Innovative Immunotherapies
  • [H2] Learn how our science is changing what’s possible
  • [H2] Stage III MSS Colorectal Cancer
  • [H2] Merkel Cell Carcinoma
  • [H2] Undifferentiated Pleomorphic Sarcoma
  • [H2] Bringing the Power of Immunotherapy
to More Patients
  • [H2] “30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
  • [H2] In the News
  • [H2] Get answers about clinical trials, patient access, and more
  • [H2] By the Numbers
  • [H3] OncoDaily
  • [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
  • [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
  • [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
  • [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
  • [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
  • [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
  • [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
  • [H3] Redefining Cancer Care
  • [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
  • [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
  • [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
  • [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
  • [H3] Immunotherapies break into cold colorectal cancers at ASCO
  • [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
  • [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
  • [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
  • [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
  • [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
  • [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
  • [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
  • [H3] New Strategies for Targeting CTLA-4 Emerge
  • [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
  • [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
  • [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
  • [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
  • [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
  • [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
  • [H3] Unpacking the Latest Research in Gastrointestinal Cancers
  • [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
  • [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
  • [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
  • [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
  • [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
  • [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
  • [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
  • [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
  • [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
  • [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
  • [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
  • [H3] Redefining Cancer Care
  • [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
  • [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
  • [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
  • [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
  • [H3] Immunotherapies break into cold colorectal cancers at ASCO
  • [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
  • [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
  • [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
  • [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
  • [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
  • [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
  • [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
  • [H3] New Strategies for Targeting CTLA-4 Emerge
  • [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
  • [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
  • [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
  • [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
  • [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
  • [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
  • [H3] Unpacking the Latest Research in Gastrointestinal Cancers
  • [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
  • [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
  • [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
  • [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer

Bilder

Vi hittade 164 bilder på denna webbsida.

164 alt attribut är tomma eller saknas. Lägg till alternativ text så att sökmotorer enklare kan förstå innehållet i dina bilder.

Text/HTML Ratio

Ratio : 5%

Denna sidas förhållande mellan text till HTML-kod är lägre än 15 procent, vilket innebär att din webbplats troligen behöver mer textinnehåll.

Flash

Perfekt, inga Flash-innehåll har upptäckts på denna sida.

Iframe

Synd, du har Iframes på webbsidorna vilket innebär att innehållet i en Iframe inte kan indexeras.

URL Rewrite

Bra. Dina adressfält ser bra ut!

Understreck i URLen

Perfekt! Inga understreck upptäcktes i din webbadress.

In-page länkar

Vi hittade totalt 41 länkar inklusive 0 länk(ar) till filer

Anchor Typ Juice
- Interna Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
- Externa Passing Juice
Opt-out preferences Interna Passing Juice
Terms and Conditions of Use Interna Passing Juice
Privacy Policy Interna Passing Juice
Community Guidelines Interna Passing Juice
Access to Investigational Medicines Policy Interna Passing Juice
Report Adverse Event Interna Passing Juice
Investor Portal Interna Passing Juice

SEO Nyckelord

Nyckelord Moln

immunotherapy agenus access cancer patient botensilimab january news colorectal balstilimab

Nyckelord Konsistens

Nyckelord Innehåll Titel Nyckelord Beskrivning Rubriker
cancer 48
access 29
botensilimab 28
agenus 25
colorectal 23

Användbarhet

Url

Domän : agenusbio.com

Längd : 13

Favikon

Bra, din webbplats har en favicon.

Utskriftbart

Vi kunde inte hitta CSS för utskrifter.

Språk

Bra. Ditt angivna språk är en.

Dublin Core

Denna sida drar inte nytta utav Dublin Core.

Dokument

Doctype

HTML 5

Encoding

Perfekt. Din deklarerade teckenuppsättning är UTF-8.

W3C Validity

Errors : 0

Varningar : 0

E-post Sekretess

Varning! Minst en e-postadress har påträffats i klartext. Använd gratis antispam skydd för att dölja e-post från spammare.

Föråldrad HTML

Bra! Vi har inte hittat några föråldrad HTML taggar i din HTML.

Hastighets Tips

Utmärkt, din webbplats använder inga nästlade tabeller.
Synd, din webbplats använder sig utav inline stilar.
Bra, din webbplats har få CSS-filer.
Synd, din webbplats har för många JS filer (fler än 6 stycken).
Perfekt, din webbplats utnyttjar gzip.

Mobil

Mobiloptimering

Apple Ikon
Meta Viewport Tagg
Flash innehåll

Optimering

XML Sitemap

Bra, din webbplats har en XML sitemap.

https://www.agenusbio.com/sitemap.xml

Robots.txt

https://agenusbio.com/robots.txt

Bra, din webbplats har en robots.txt fil.

Analytics

Saknas

Vi hittade inte någon analysverktyg på din webbplats.

Webbanalys program kan mäta besökare på din webbplats. Du bör ha minst ett analysverktyg installerat, men det kan också vara en bra ide att installera två för att dubbelkolla uppgifterna.

PageSpeed Insights

Enhet
Kategorier

Free SEO Testing Tool

Free SEO Testing Tool är en fri SEO verktyg som hjälper dig att analysera din webbplats